Presentation is loading. Please wait.

Presentation is loading. Please wait.

Time to disease progression or death in a) the whole Bosentan Use in Interstitial Lung Disease (BUILD)-1 study population and b) the subpopulation with.

Similar presentations


Presentation on theme: "Time to disease progression or death in a) the whole Bosentan Use in Interstitial Lung Disease (BUILD)-1 study population and b) the subpopulation with."— Presentation transcript:

1 Time to disease progression or death in a) the whole Bosentan Use in Interstitial Lung Disease (BUILD)-1 study population and b) the subpopulation with biopsy-proven idiopathic pulmonary fibrosis. ·········: treatment with bosentan, ––––: placebo. a) Hazard... Time to disease progression or death in a) the whole Bosentan Use in Interstitial Lung Disease (BUILD)-1 study population and b) the subpopulation with biopsy-proven idiopathic pulmonary fibrosis. ·········: treatment with bosentan, ––––: placebo. a) Hazard ratio (95% confidence interval): (0.328–1.144); p =  b) Hazard ratio (95% confidence interval): (0.126–0.789); p = 0.009. K. K. Brown, and A. U. Wells Eur Respir Rev 2008;17: ©2008 by European Respiratory Society


Download ppt "Time to disease progression or death in a) the whole Bosentan Use in Interstitial Lung Disease (BUILD)-1 study population and b) the subpopulation with."

Similar presentations


Ads by Google